Levetiracetam Clinical Pharmacokinetic Monitoring in Pediatric Patients with Epilepsy

Clinical Pharmacokinetics

Volumn 56, Issue 11, 2017, Pages 1267-1285

  Tan, Jason ^a,b   Paquette, Vanessa ^b   Levine, Marc ^a   Ensom, Mary H H ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b CHILDREN S AND WOMEN S HEALTH CENTRE OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

LEVETIRACETAM; ANTICONVULSIVE AGENT; ETIRACETAM; PIRACETAM;

BENIGN CHILDHOOD EPILEPSY; CHILD; CLINICAL ASSESSMENT; CLINICAL DECISION MAKING; CLINICAL PRACTICE; CONCENTRATION RESPONSE; DRUG DETERMINATION; DRUG EFFICACY; DRUG INDICATION; DRUG MONITORING; DRUG SAFETY; FOCAL EPILEPSY; GENERALIZED EPILEPSY; HUMAN; MEASUREMENT ACCURACY; MEASUREMENT PRECISION; MONOTHERAPY; PHARMACODYNAMICS; PHARMACOKINETIC PARAMETERS; PRIORITY JOURNAL; REVIEW; TONIC CLONIC SEIZURE; TREATMENT DURATION; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; BLOOD; EPILEPSY; PEDIATRICS; PROCEDURES;

ANTICONVULSANTS; DRUG MONITORING; EPILEPSY; HUMANS; PEDIATRICS; PIRACETAM;

EID: 85016124312     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-017-0537-1     Document Type: Review

References (76)

1. Shinnar S, Pellock JM. Update on the epidemiology and prognosis of pediatric epilepsy. J Child Neurol. 2002;17:S4–17.
2. Trinka E. Ideal characteristics of an antiepileptic drug: how do these impact treatment decisions for individual patients? Acta Neurol Scand. 2012;126:10–8.
3. European Medicines Agency. Keppra: EPAR – scientific discussion. European Medicines Agency; 2005. pp. 17–19.
4. Crepeau AZ, Treiman DM. Levetiracetam: a comprehensive review. Expert Rev Neurother. 2010;10:159–71.
5. Shorvon SD, Lowenthal A, Janz D, et al. Multicentre, double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. Epilepsia. 2000;41:1179–86.
6. Cereghino JJ, Biton V, Bou-Khalil B, et al. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology. 2000;55:236–42.
7. Ben-Menachem E, Falter U. Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multi-centre, double-blind, responder selected study evaluating monotherapy. Epilepsia. 2000;41:1279–83.
8. Glauser TA, Ayala R, Elterman RD, et al. Double-blind, placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures. Neurology. 2006;66:1654–60.
9. Pina-Garza JE, Nordli DR Jr, Rating D, et al. Adjunctive levetiracetam in infants and young children with refractory partial-onset seizures. Epilepsia. 2009;50:1141–9.
10. Ndegwa S. Levetiracetam for the treatment of epilepsy [Environmental Scan issue 30]. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2011.
11. Wright C, Downing J, Mungall D, et al. Clinical pharmacology and pharmacokinetics of levetiracetam. Front Neurol. 2013;4:192.
12. Patsalos PN. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol Ther. 2000;85:77–85.
13. Pellock JM, Glauser TA, Bebin EM, et al. Pharmacokinetic study of levetiracetam in children. Epilepsia. 2001;42:1574–9.
14. Ensom MHH, Davis GA, Cropp CD, Ensom RJ. Clinical pharmacokinetics in the 21st century. Does the evidence support definitive outcomes? Clin Pharmacokinet. 1998;34:265–79.
15. Pina-Garza JE, Schiemann-Delgado J, Yang H, et al. Adjunctive levetiracetam in patients aged 1 month to <4 years with parital-onset seizures: subpopulation analysis of a prospective, open-label extension study of up to 48 weeks. Clin Ther. 2010;32:1935–50.
16. Levisohn PM, Mintz M, Hunter SJ, et al. Neurocognitive effects of adjunctive levetiracetam in children with partial-onset seizures: a randomized double-blind, placebo-controlled, noninferiority trial. Epilepsia. 2009;50:2377–89.
17. Schiemann-Delgado J, Yang H, de la Loge C, et al. A long-term open-label extension study assessing cognition and behaviour, tolerability, safety, and efficacy of adjunctive levetiracetam in children aged 4 to 16 years with partial-onset seizures. J Child Neurol. 2012;27:80–9.
18. Mbizvo GK, Dixon P, Hutton JL, Marson AG. Levetiracetam add-on for drug-resistant focal epilepsy: an updated Cochrane review. Cochrane Database Syst Rev. 2012;(9):CD001901. doi:10.1002/14651858.CD001901.pub2
19. Rosenow F, Schade-Brittinger C, Burchardi N, et al. The LaLiMo trial: lamotrigine compared with levetiracetam in the initial 26 weeks of monotherapy for focal and generalised epilepsy: an open-label, prospective, randomised controlled multicenter study. J Neurol Neurosurg Psychiatry. 2012;83:1093–8.
20. Jung DE, Yu R, Yoon JR, et al. Neuropsychological effects of levetiracetam and carbamazepine in children with focal epilepsy. Neurology. 2015;84:2312–9.
21. Chung S, Ceja H, Gawłowicz J, Avakyan G, McShea C, Schiemann J, et al. Levetiracetam extended release conversion to monotherapy for the treatment of patients with partial-onset seizures: A double-blind, randomised, multicentre, historical control study. Epilepsy Res. 2012;101:92–102.
22. French JA, Wang S, Warnock B, Temkin N. Historical control monotherapy design in the treatment of epilepsy. Epilepsia. 2010;51:1936–43.
23. Chung S, Ceja H, Gawłowicz J, McShea C, Schiemann J, Lu S. Levetiracetam extended release for the treatment of patients with partial-onset seizures: a long-term, open-label follow-up study. Epilepsy Res. 2016;120:7–12.
24. Peltola J, Coetzee C, Jiménez F, Litovchenko T, Ramaratnam S, Zaslavaskiy L, et al. Once-daily extended-release levetiracetam as adjunctive treatment of partial-onset seizures in patients with epilepsy: a double-blind, randomized, placebo-controlled trial. Epilepsia. 2009;50:406–14.
25. Coppola G, Franzoni E, Verrotti A, Garone C, Sarajlija J, Operta FF, et al. Levetiracetam or oxcarbazepine as monotherapy in newly diagnosed benign epilepsy of childhood with centrotemporal spikes (BECTS): an open-label, parallel group trial. Brain Dev. 2007;29:281–4.
26. Xiao F, An D, Deng H, Chen S, Ren J, Zhou D. Evaluation of levetiracetam and valproic acid as low-dose monotherapies for children with typical benign childhood epilepsy with centrotemporal spikes (BECTS). Seizure. 2014;23:756–61.
27. Fattore C, Boniver C, Capovilla G, et al. A multicenter, randomized, placebo-controlled trial of levetiracetam in children and adolescents with newly diagnosed absence epilepsy. Epilepsia. 2011;52:802–9.
28. Noachtar S, Andermann E, Meyvisch P, et al. Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures. Neurology. 2008;70:607–16.
29. Berkovic SF, Knowlton RC, Leroy RF, et al. Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy. Neurology. 2007;69:1751–60.
30. Cormier J, Chu CJ. Safety and efficacy of levetiracetam for the treatment of partial onset seizures in children from one month of age. Neuropsychiatr Dis Treat. 2013;9:295–306.
31. Bertsche A, Neininger MP, Dahse AJ, Syrbe S, Bernhard MK, Frontini R, et al. Initial anticonvulsant monotherapy in routine care of children and adolescents: levetiracetam fails more frequently than valproate and oxcarbazepine due to a lack of effectiveness. Eur J Pediatr. 2014;173:87–92.
32. Vermeij TAC, Edelbroek PM. High-performance liquid chromatographic and megabore gas—liquid chromatographic determination of levetiracetam (ucb L059) in human serum after solid-phase extraction. J Chromatogr B. 1994;662:134–9.
33. Ratnaraj N, Doheny HC, Patsalos PN. A micromethod for the determination of the new antiepileptic drug levetiracetam (ucb L059) in serum or plasma by high performance liquid chromatography. Ther Drug Monit. 1996;18:154–7.
34. Martens-Lobenhoffer J, Bode-Böger SM. Determination of levetiracetam in human plasma with minimal sample pretreatment. J Chromatogr B. 2005;819:197–200.
35. Juenke JM, Brown PI, Urry FM, McMillin GA. Drug monitoring and toxicology: a procedure for the monitoring of levetiracetam and zonisamide by HPLC-UV. J Anal Toxicol. 2006;30:27–30.
36. Contin M, Mohamed S, Albani F, Riva R, Baruzzi A. Simple and validated HPLC–UV analysis of levetiracetam in deproteinized plasma of patients with epilepsy. J Chromatogr B. 2008;873:129–32.
37. Baldelli S, Cattaneo D, Giodini L, Baietto L, Di Perri G, D’Avolio A, et al. Development and validation of a HPLC-UV method for the quantification of antiepileptic drugs in dried plasma spots. Clin Chem Lab Med. 2015;53:435–44.
38. Jain DS, Subbaiah G, Sanyal M, Pal U, Shrivastav PS. Determination of levetiracetam in human plasma by liquid chromatography/electrospray tandem mass spectrometry and its application to bioequivalence studies. Rapid Commun Mass Spectrom. 2006;15(20):2539–47.
39. Guo T, Oswald LM, Mendu DR, Soldin SJ. Determination of levetiracetam in human plasma/serum/saliva by liquid chromatography–electrospray tandem mass spectrometry. Clin Chim Acta. 2007;375:115–8.
40. Matar KM. Quantification of levetiracetam in human plasma by liquid chromatography–tandem mass spectrometry: application to therapeutic drug monitoring. J Pharmaceut Biomed. 2008;48:822–8.
41. Blonk MI, van der Nagel BC, Smit LS, Mathot RAA. Quantification of levetiracetam in plasma of neonates by ultra performance liquid chromatography–tandem mass spectrometry. J Chromatogr B. 2010;878:675–81.
42. Antonilli L, Brusadin V, Filipponi F, Guglielmi R, Nencini P. Development and validation of an analytical method based on high performance thin layer chromatography for the simultaneous determination of lamotrigine, zonisamide and levetiracetam in human plasma. J Pharmaceut Biomed. 2011;56:763–70.
43. Juenke JM, Brown PI, Johnson-Davis KL, McMillin GA. Simultaneous quantification of levetiracetam and gabapentin in plasma by ultra-pressure liquid chromatography coupled with tandem mass spectrometry detection. Ther Drug Monit. 2011;33:209–13.
44. Juenke JM, McGraw JP, McMillin GA, Johnson-Davis KL. Performance characteristics and patient comparison of the ARK Diagnostics levetiracetam immunoassay with an ultra-high performance liquid chromatography with tandem mass spectrometry detection method. Clin Chim Acta. 2012;413:529–31.
45. Yeap L-L, Lo Y-L. Rapid and simultaneous quantification of levetiracetam and its carboxylic metabolite in human plasma by liquid chromatography tandem mass spectrometry. PLoS ONE. 2014;9:e111544.
46. Pucci V, Bugamelli F, Mandrioli R, Ferranti A, Kenndler E, Raggi MA. High-performance liquid chromatographic determination of Levetiracetam in human plasma: comparison of different sample clean-up procedures. Biomed Chrom. 2004;18:37–44.
47. Zufía L, Aldaz A, Ibáñez N, Giráldez J, Viteri C. LC method for therapeutic drug monitoring of levetiracetam: evaluation of the assay performance and validation of its application in the routine area. Clin Biochem. 2010;43:473–82.
48. Reineks EZ, Lawson SE, Lembright KE, Wang S. Performance characteristics of a new levetiracetam immunoassay and method comparison with a high-performance liquid chromatography method. Ther Drug Monit. 2011;33:124–7.
49. Mecarelli O, Voti PL, Pro S, Romolo FS, Rotolo M, Pulitano P, et al. Saliva and serum levetiracetam concentrations in patients with epilepsy. Ther Drug Monit. 2007;29:313–8.
50. Nikolaou P, Papoutsis I, Dona A, Spiliopoulou C, Athanaselis S. Development and validation of a GC/MS method for the simultaneous determination of levetiracetam and lamotrigine in whole blood. J Pharmaceut Biomed. 2015;102:25–32.
51. Greiner-Sosanko E, Giannoutsos S, Lower DR, Virji MA, Krasowski MD. Drug monitoring: simultaneous analysis of lamotrigine, oxcarbazepine, 10-hydroxycarbazepine, and zonisamide by HPLC-UV and a rapid GC method using a nitrogen-phosphorus detector for levetiracetam. J Chromatogr Sci. 2007;45:616–22.
52. Bianchi V, Arfini C, Vidali M. Therapeutic drug monitoring of levetiracetam: comparison of a novel immunoassay with an HPLC method. Ther Drug Monit. 2014;36:681–5.
53. Krasowski MD. Therapeutic drug monitoring of the newer anti-epilepsy medications. Pharm J. 2010;3:1909–35.
54. Iwasaki T, Toki T, Nonoda Y, Ishii M. The efficacy of levetiracetam for focal seizures and its blood levels in children. Brain Dev. 2015;37:773–9.
55. Mathew B, Prabha R, Saravanakumar K, Thomas M, Fleming D. An initial experience with therapeutic drug monitoring of levetiracetam as reported from a pediatric clinical setting in India. Neurol India. 2012;60:146.
56. Giroux PC, Salas-Prato M, Théorêt Y, Carmant L. Levetiracetam in children with refractory epilepsy: lack of correlation between plasma concentration and efficacy. Seizure. 2009;18:559–63.
57. Sheinberg R, Heyman E, Dagan Z, Youngster I, Kohn E, Gandelman-Marton R, et al. Correlation between efficacy of levetiracetam and serum levels among children with refractory epilepsy. Pediatr Neurol. 2015;52:624–8.
58. Lancelin F, Franchon E, Kraoul L, Garciau I, Brovedani S, Tabaouti K, et al. Therapeutic drug monitoring of levetiracetam by high-performance liquid chromatography with photodiode array ultraviolet detection: preliminary observations on correlation between plasma concentration and clinical response in patients with refractory epilepsy. Ther Drug Monit. 2007;29:576–83.
59. Leppik IE, Rarick JO, Walczak TS, Tran TA, White JR, Gumnit JR. Effective levetiracetam doses and serum concentrations: age effects. Epilepsia. 2002;43:240.
60. St Louis EK. Monitoring antiepileptic drugs: a level-headed approach. Curr Neuropharmacol. 2009;7:115–9.
61. Mohanraj R, Brodie MJ. Measuring the efficacy of antiepileptic drugs. Seizure. 2003;12:413–43.
62. Boylan GB, Stevenson NJ, Vanhatalo S. Monitoring neonatal seizures. Semin Fetal Neonatal Med. 2013;18:202–8.
63. Claassen J, Mayer SA, Kowalski RG, Emerson RG, Hirsch LJ. Detection of electrographic seizures with continuous EEG monitoring in critically ill patients. Neurology. 2004;62:1743–8.
64. Stepanova D, Beran RG. The benefits of antiepileptic drug (AED) blood level monitoring to complement clinical management of people with epilepsy. Epilepsy Behav. 2015;42:7–9.
65. Obeid M, Pong AW. Efficacy and tolerability of high oral doses of levetiracetam in children with epilepsy. Epilepsy Res. 2010;91:101–5.
66. Patsalos PN. Clinical pharmacokinetics of levetiracetam. Clin Pharmacokinet. 2004;43:707–24.
67. Lu H, Rosenbaum S. Developmental pharmacokinetics in pediatric populations. J Pediatr Pharmacol Ther. 2014;19:262–76.
68. Italiano D, Perucca E. Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age: an update. Clin Pharmacokinet. 2013;52:627–45.
69. Dahlin MG, Wide K, Ohman I. Age and comedications influence levetiracetam pharmacokinetics in children. Pediatr Neurol. 2010;43:231–5.
70. Landmark CJ, Baftiu A, Tysse I, Valso B, Larsson PG, Rytter E, et al. Pharmacokinetic variability of four newer antiepileptic drugs, lamotrigine, levetiracetam, oxcarbazepine, and topiramate: a comparison of the impact of age and comedication. Ther Drug Monit. 2012;34:440–5.
71. Toublanc N, Sargentini-Maier ML, Lacroix B, Jacqmin P, Stockis A. Retrospective population pharmacokinetic analysis of levetiracetam in children and adolescents with epilepsy. Clin Pharmacokinet. 2008;47:333–41.
72. Toublanc N, Lacroix BD, Yamamoto J. Development of an integrated population pharmacokinetic model for oral levetiracetam in populations of various ages and ethnicities. Drug Metab Pharmacokinet. 2014;29:61–8.
73. Wang Y, Wang L, Lu W, Shang D, Wei M, Wu Y. Population pharmacokinetics modeling of levetiracetam in Chinese children with epilepsy. Acta Pharmacol Sin. 2012;33:845–51.
74. Chhun S, Jullien V, Rey E, Dulac O, Chiron C, Pons G. Population pharmacokinetics of levetiracetam and dosing recommendation in children with epilepsy. Epilepsia. 2009;50:1150–7.
75. Krumholz A, Wiebe S, Gronseth GS, Gloss DS, Sanchez AM, Kabir AA, et al. Evidence-based guideline: management of an unprovoked first seizure in adults. Neurology. 2015;84:1705–13.
76. Patsalos PN, Berry DJ, Bourgeois BFD, Cloyd JC, Glauser TA, Johannessen SI, et al. Antiepileptic drugs—best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia. 2008;49:1239–79.